Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results

Ophthalmology

Volumn 119, Issue 7, 2012, Pages 1388-1398

  Martin, Daniel F ^a   Maguire, Maureen G ^b   Fine, Stuart L ^c   Ying, Gui Shuang ^b   Jaffe, Glenn J ^d   Grunwald, Juan E ^b   Toth, Cynthia ^d   Redford, Maryann ^e   Ferris III, Frederick L ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY   (United States)

^e NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOEMBOLIC STROKE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG FATALITY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART INFARCTION; HERNIA; HUMAN; HYPERTENSION; INFECTION; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RISK; SOLID TUMOR; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84863320414     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.03.053     Document Type: Article

References (17)

1. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
2. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
3. R.J. Brechner, P.J. Rosenfeld, J.D. Babish, S. Caplan Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service Part B claims file Am J Ophthalmol 151 2011 887 895
4. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
5. Office of the Inspector General, Department of Health and Human Services Review of Medicare Part B Avastin and Lucentis treatments for age-related macular degeneration (A-01-10-00514) [letter] September 2011 http://oig.hhs.gov/oas/reports/region10/11000514.pdf Accessed February 16, 2012
6. Antiplatelet Trialists' Collaboration Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
7. D.B. Rubin Multiple Imputation for Nonresponse in Surveys 1987 Wiley New York 15 22
8. S.L. Zeger, K.Y. Liang Longitudinal data analysis for discrete and continuous outcomes Biometrics 42 1986 121 130
9. D.R. Cox Regression models and life-tables J R Stat Soc Ser B 34 1972 187 220
10. P.R. Rosenbaum, D.B. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
11. H.X. Chen, J.N. Cleck Adverse effects of anticancer agents that target the VEGF pathway Nat Rev Clin Oncol 6 2009 465 477
12. S.R. Nalluri, D. Chu, R. Keresztes Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2008 2277 2285
13. Macular Photocoagulation Study Group Laser photocoagulation of subfoveal neovascular lesions of age related macular degeneration: updated findings from two clinical trials Arch Ophthalmol 111 1993 1200 1209
14. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2 Arch Ophthalmol 119 2001 198 207
15. Verteporfin in Photodynamic Therapy Study Group Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy report 2 Am J Ophthalmol 131 2001 541 560
16. Eyetech Study Group Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results Ophthalmology 110 2003 979 986
17. United States Senate Special Committee on Aging Statement of Jonathan Blum, Deputy Administrator and Director, Center for Medicare and Medicaid Services, on sustaining the Medicare program through lower costs, before the United States Senate Special Committee on Aging July 21, 2011 http://aging.senate.gov/events/hr236jb.pdf Accessed February 10, 2012